摘要
目的 探讨扁平苔藓的患病因素及免疫球蛋白(IgG)、补体C3、C4水平在该病诊断中的作用。方法 选择于2021年2~10月在河北工程大学附属医院就诊的扁平苔藓患者共40例(轻症20例,重症20例),从河北工程大学附属医院的工作人员中选择20名志愿者作为健康对照组,采用速率散射比浊法检测扁平苔藓患者及健康组成员血清中IgG及补体C3、C4的水平。比较轻症组、重症组、健康组成员以及轻症、重症患者治愈后各指标的差异。结果 轻、重症组的IgG水平较健康组明显升高,差异均有统计学意义(P<0.05)。重症组的IgG水平较轻症组亦明显升高,差异均有统计学意义(P<0.05);轻、重症组的补体C3,C4水平较健康组明显降低,差异均有统计学意义(P<0.05)。治愈后轻症组的IgG水平较明显降低,补体C3,C4水平较轻症组明显升高,差异均有统计学意义(P<0.05)。治愈后重症组的IgG水平较重症组明显降低,C3、C4水平较重症组明显升高,并异均有统计学意义(P<0.05)。轻、重症组治愈后IgG,补体C3、C4水平与健康组比较,差异无统计学意义(P>0.05)。结论 扁平苔藓的发病与患者自身免疫相关,患者血清IgG水平和补体C3、C4水在扁平苔藓的诊断中具有临床价值。
Objective To explore the predisposing factors of lichen planus(LP) and the diagnostic potential of immunoglobulin(IgG) and complement C3 and C4 levels in LP patients.Methods A total of 40 patients with lichen planus treated in the Affiliated Hospital of Hebei Engineering University from February 2021 to October 2021 were selected,including 20 mild cases and 20 severe cases.During the same period,20 healthy volunteers were selected from the staff of the Affiliated Hospital of Hebei Engineering University as the control group.Serum levels of IgG,C3 and C4 were measured by rate nephelometry.Their changes in mild lichen planus patients,severe lichen planus patients and healthy volunteers were compared.Results The IgG level in mild and severe LP patients was significantly higher than that of healthy volunteers(P<0.05),which was significantly higher in mild cases than that of severe cases(P<0.05).C3 and C4 levels in mild and severe LP patients were significantly higher than those of healthy volunteers(P<0.05).After being cured,IgG level was significantly reduced in mild and severe LP patients,while C3 and C4 were significantly elevated(P<0.05).IgG,C3 and C4 levels were comparable in cured mild and severe LP patients,and healthy volunteers(P>0.05).Conclusion The pathogenesis of LP is related to the patient’s autoimmunity.The serum IgG level and complement C3 and C4 have diagnostic potential of LP.
作者
焦丽艳
刘小娟
陈雪皎
钱华
李江慧
杜红霞
苗国英
JIAO Liyan;LIU Xiaojuan;CHEN Xuejiao(Affiliated Hospital of Hebei Engineering University,Hebei,Handan 056002,China)
出处
《河北医药》
CAS
2023年第2期210-213,共4页
Hebei Medical Journal